Extended Data Figure 3 (related to Figure 1). Additional characterization of TRIM37 expression and synthetic lethality in breast cancer cell lines and patient-derived organoids (PDOs).

(A) Immunoblot showing TRIM37 protein levels in the indicated 17q23-amplified cell lines (MDA-MB-361, BT474, MCF-7) and non-17q23-amplified cell lines (BT549, MDA-MB-231, MDA-MB-436) expressing control, or TRIM37-targeting, shRNA. β-Actin, loading control. Representative data; n = 3, biological replicates. For gel source data, see Supplementary Figure 1.

(B) Clonogenic survival of 17q23-amplified and non-17q23-amplified cell lines treated with DMSO (control) or 125 nM centrinone (PLK4i). Representative data; n = 3, biological replicates.

(C) Images of DMSO or PLK4i-treated MDA-MB-361 and BT474 cells expressing control, or TRIM37-targeting, shRNA. Scale bars, 200 μm. Representative data; n = 3, biological replicates.

(D) Left, Representative flow cytometric DNA content analysis in DMSO or PLK4i-treated MDA-MB-361 and BT474 cells. Percentages of sub-G1 events are indicated. Right, percentage of sub-G1 cells across n = 3, biological replicates. P values, unpaired two-tailed t-test. Mean ± s.e.m.

(E) TRIM37 gene expression in PDOs. Gene expression is reported as a z-score derived from RNA-Seq datasets across n = 22, independent biological samples.

(F) Viability of patient-derived breast tumour organoids following a 14 day exposure to the indicated concentrations of centrinone. Data from n = 2 biological replicates are shown. Mean ± s.e.m.

(G) Immunoblot showing TRIM37 protein levels in PDOs. β-Actin, loading control. Data from n = 1, biological replicate. For gel source data, see Supplementary Figure 1.

(H) Viability of 3D-cultures of the indicated cell lines following a 14 day exposure to the indicated concentrations of centrinone. Left panel, n = 2, biological replicates, Mean ± s.e.m. Right panel, n = 4, technical replicates, Mean ± s.e.m.